July 4, 2022
EPS Holdings, Inc.
EPS Corporation
EPS International Holdings Co., Ltd.
News Release

EPS Group Forms Strategic Reorganization for CRO Business
EPS International Holdings Co., Ltd. (“EPS International”, hereafter) and EPS Corporation (“EPS”,hereafter), both of which are wholly owned subsidiaries of EPS Holdings, Inc., announced that EPS
International and EPS have decided to merge through an absorption-type merger, with EPS as thesurviving company and EPS International as the absorbed company on 1st September 2022.
1.Purpose of the Reorganization
Last year, the EPS Group celebrated its 30th anniversary and conducted a management buyout(MBO), moving toward "The New EPS". The reorganization of the domestic CRO business wascompleted on schedule as of 1st July 2022, and this reorganization is related to the overseas businessfollowing the domestic business.
EPS International has been expanding its services to overseas clients, especially inbound projects
from Europe, the U.S., and China, focusing not only on functional services, in which somedevelopment functions are outsourced in Japan, but also on full services requiring an in-country
clinical trial manager. Recently, however, the business environment surrounding CROs has been
undergoing significant changes.
As years go by, Multi-National Clinical Trials are becoming the mainstream of clinical trials, andthe use of real-world data, including patient registry data, is being expanded. Cross-border data
sharing is expected to be further accelerated in the future as globalization progresses and the barriers
between clinical trials and the real world are becoming lower.
The purpose of this reorganization is to provide solutions that meet the needs of a New Era in both
domestic and overseas operations by integrating the experience, project management and know-howof EPS, a leading company in the CRO industry that provides drug development support services inJapan, and EPS International, which focuses on full-service drug development support for overseasclients.
The EPS Group will contribute to the further progress of the health industry by providing highquality services as a good partner to its customers, as well as strengthening the local medical systemand improving people's health.
2.Scheduled Merging Effective Date
1st September 2022
3.Overview of Reorganization
Surviving company

Absorbed company

Name

EPS Corporation

EPS International Holdings Co., Ltd.

Address

2-23 Shimomiyabicho, Shinjuku-ku,

1-8 Tsukudocho, Shinjuku-ku, Tokyo,

Tokyo, 162-0822, Japan

162-0821, Japan

Akira SASA

Tomohisa HAYAKAWA

CRO business, Post-marketing

CRO business mainly for overseer’s

surveillance and Pharmacovigilanceclients, In-Country Clinical CaretakerSupport(ICCC) in Japan

3187

228

CapitalJPY 100,000,000

JPY 100,000,000

Stockholder

EPS Holdings, Inc. (100%)

EPS Holdings, Inc. (100%)

Representative
DirectorBusiness

Number ofEmployees**As of 1st July 2022

About EPS group
Since its establishment in 1991 as one of pioneering CROs, EPS Group has been a Healthcare Solution
Provider to pharmaceutical companies, medical device manufacturers, hospitals and clinics, andacademia with various solutions from development to marketing, sales, consultation covering Asia
centered in China and new values created in big data & AI, regenerative medicine, etc. The strength ofEPS lies in the fact that it has the greatest presence in Japan. In Asia, the company has multiple overseas
offices and has focused particularly on solidifying its sites in the respective Asian countries, providing
clinical development support services as well as SMO services.
Contact:EPS Holdings, Inc.
Corporate Communications Office
Email: pr@eps.co.jp